Trials / Completed
CompletedNCT04956432
A Multicentre, Randomized, Double-blind, Allopurinol Controlled Study to Evaluate the Efficacy and Safety of SHR4640 in Subjects With Gout
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 779 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the serum uric acid lowering effects and safety of SHR4640 compared to Allopurinol in subjects with gout.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR4640 | SHR4640 Dose 1 ,tablets, QD |
| DRUG | Allopurinol | Allopurinol 300mg, tablets, QD |
Timeline
- Start date
- 2021-06-15
- Primary completion
- 2023-12-13
- Completion
- 2024-08-23
- First posted
- 2021-07-09
- Last updated
- 2025-01-24
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04956432. Inclusion in this directory is not an endorsement.